Transglutaminase inhibitors and methods of use thereof

1. A pharmaceutical formulation comprising a tTGase inhibitor of the formula:

wherein R is a substituted or unsubstituted heteroaryl; and

a pharmaceutically acceptable excipient for oral or injectable delivery.

2. The formulation of claim 1 , wherein said tTGase inhibitor is [1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2-(5-fluoro-1H-indol-3-yl)-ethyl]-carbamic acid quinolin-3-ylmethyl ester.

3. The formulation of claim 1 , wherein the formulation is an oral formulation.

4. The formulation of claim 3 , wherein said oral formulation comprises an enteric coating.

5. The formulation of claim 3 , wherein said oral formulation comprises engineered polymer microspheres made of biologically erodable polymers.

6. The formulation of claim 1 , wherein the effective dose is 0.01 mg to 500 mg V/kg body weight per day.

7. The formulation of claim 1 , wherein said tTGase inhibitor is admixed with food.